| Code | CSB-RA023981MB8HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to IMG-007, targeting TNFRSF4 (tumor necrosis factor receptor superfamily member 4), also known as OX40 or CD134. TNFRSF4 is a costimulatory receptor expressed primarily on activated T cells that plays a critical role in T cell activation, proliferation, and survival. Upon binding to its ligand OX40L, this receptor enhances T cell-mediated immune responses and promotes immunological memory formation. TNFRSF4 has significant implications in cancer immunotherapy, autoimmune diseases, and inflammatory conditions, making it an important therapeutic target for modulating immune responses.
IMG-007 represents an investigational agonistic antibody that has been explored for its potential to enhance anti-tumor immunity by stimulating T cell responses through TNFRSF4 engagement. This biosimilar antibody provides researchers with a valuable tool for investigating TNFRSF4-mediated signaling pathways, studying T cell biology, and exploring immune checkpoint modulation in various disease models. It supports investigations into combination immunotherapy strategies and mechanisms of immune regulation in oncology and immunology research.
There are currently no reviews for this product.